Real World Cases Prove that XARELTO lessens the risk of recurrent venous thromboembolism in Patients with Morbidly Obesity

Publisher: The Insight Partners

The recent real-world case study performed in New Jersey by Johnson & Johnson Company has all the evidences that XARELTO can efficiently lessen the risk of recurrent blood clots as well as overall medical costs within the patients with morbidly obesity. Also, the results even conclude that the patients taking XARELTO have better condition than those with warfarin.

In the United States nearly 40 percent of the populace is suffering from obesity as well as around 8 percent with morbid obese. Patients who are obese have more chances of VTE (recurrent venous thromboembolism) as compared to those who are non-obese. Moreover, morbidly obese patients are often treated with primal anticoagulants, like warfarin. Also, require added specialist care than the patients with normal weight.

XARELTO

This is the prescription medicine mostly used for:

• Decreasing the possibility of stroke as well as blood clots among the people with medical condition known as atrial fibrillation which is not associated with the heart valve problem. Due to atrial fibrillation, portion of human heart doesn’t function. This might lead in forming blood clots that can affect brain resulting in stroke or even any other body part.

• For treating blood clots within the veins of legs known as deep vein thrombosis (DVT) or even pulmonary embolism (PE).

• Lessens the jeopardy of forming blood clots again and again amongst the patients having prolonging risk for DVT or else PE after the treatment of 6 months gets completed for blood clots.

• Enables preventing any formation of blood clot in legs or lungs of patients who have recently been through hip/knee replacement surgery.

Case Study:

Over and above 5,000 patients with morbidly obesity (having BMI (body mass index) of ≥40) were involved in the analysis. And of all half were treated with XARELTO and rest half were given warfarin.

There were nearly 2,890 in line pairs within ITT (intent-to-treat) analysis as well as almost 2,832 pairs within on-treatment examination.

Below are a few observations made from the ITT examination:

• Recurrent VTE: The possibility of recurrent VTE wasn’t considerably different amongst XARELTO & warfarin (i.e.16.8 % versus 15.9 %)

• Major Bleeding: The reading also discovered that considerably very few major bleeding happenings were reported for those been treated with XARELTO as compared to those been treated with warfarin (i.e. 1.8 % versus 2.5 %)

• HRU (healthcare resource utilization): XARELTO was accompanying significantly lessee HRU as compared to warfarin treatment. Specially, hospitalizations followed lesser in case of the patients with XARELTO treatment.

• Medical Costs: XARELTO treatment generated expressively lesser HRU along with the total medical costs (including hospitalizations, outpatient, emergency room & skilled nursing facility or long-term care), with alike overall costs of healthcare between the groups­.

On the other hand, the on-treatment examination did not record as such significant difference for recurrent VTE as well as major bleeding amongst XARELTO & warfarin, having moderately lesser HRU & overall medical costs accompanying XARELTO.